Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

  • STATUS
    Recruiting
  • participants needed
    20
  • sponsor
    Jules Bordet Institute
Send
Updated on 5 August 2020
See if I qualify
renal function
measurable disease
multiple myeloma
bortezomib
carfilzomib
daratumumab
bone marrow procedure
pet/ct scan
refractory multiple myeloma
fdg-pet
fdg pet/ct

Summary

This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting peptide.

Details
Condition Multiple Myeloma, Multiple Myeloma, Lymphoproliferative Disorder
Age 18years - 100years
Treatment Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT
Clinical Study IdentifierNCT04379817
SponsorJules Bordet Institute
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age above or equal to 18 years
Written informed consent in accordance with institutional guidelines and obtained prior to any study procedures
Confirmed diagnosis of multiple myeloma according to the Salmon and Durie criteria
Has received at least 3 lines of treatment, exposed and refractory (or non-eligible) to the 5 major drugs (lenalidomid, pomalidomid, bortezomib, carfilzomib, daratumumab)
Life expectancy above 3 months
Active (relapsing or refractory) and measurable disease (on 18F-FDG PET/CT (performed within 4 weeks prior SSTR PET/CT) and biologically)
Adequate renal function with GFR above or equal to 30mL/min/1.73m
Bone marrow aspiration and biopsy sample available within 30 days prior study enrolment with positive SSTR2 IHC

Exclusion Criteria

Pregnant or lactating patients
Other active neoplastic disease
Treatment by another molecule that is object of investigation within 30 days prior SSTR PET/CT
Eastern Cooperative Oncology Group Performance Status above or equal to 3
Corticoids administration at a therapeutic level (total dose of 160 mg of dexamethasone or equivalent) two weeks prior enrolment
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

renal function
measurable disease
multiple myeloma
bortezomib
carfilzomib
daratumumab
bone marrow procedure
pet/ct scan
refractory multiple myeloma
fdg-pet
fdg pet/ct

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.